PARKINSON KASALLIGI BO‘LGAN BEMORLARDA ICHAK MIKROBIOMINING XUSUSIYATLARI
##article.subject##:
Parkinson kasalligi, ichak mikrobiomi, disbioz, «ichak–miya» o‘qi, neyroyallig‘lanish, nomotor simptomlar.##article.abstract##
Parkinson kasalligi surunkali progressiv kechuvchi neyrodegenerativ kasallik bo‘lib, u nafaqat motor, balki yaqqol nomotor buzilishlar bilan ham kechadi, ularning orasida oshqozon-ichak tizimi funksiyasidagi o‘zgarishlar muhim o‘rin egallaydi. So‘nggi yillarda Parkinson kasalligining patogenezi va progressiyasida ichak mikrobiomi hamda «ichak–miya» o‘qining o‘rni alohida e’tiborga olinmoqda. Ushbu tadqiqotning maqsadi Parkinson kasalligi bo‘lgan bemorlarda ichak mikrobiomining xususiyatlarini o‘rganish va ularning kasallikning klinik namoyonlari bilan o‘zaro bog‘liqligini baholashdan iborat. Tadqiqotga Parkinson kasalligi tashxisi qo‘yilgan bemorlar kiritilib, ularda motor va nomotor simptomlar UPDRS hamda Hoehn and Yahr shkalalari yordamida baholandi, shuningdek ichak mikrobiomining holati mikrob yuklamasi, mikrobiotik yadroning tuzilishi va disbioz belgilarini aniqlash orqali tahlil qilindi. Olingan natijalar ichak mikrobiomi tarkibida yaqqol buzilishlar mavjudligini, obligat mikrofloraning kamayishi va shartli-patogen mikroorganizmlar ulushining oshishini ko‘rsatdi, bu esa kasallik davomiyligi va klinik og‘irligi bilan bog‘liq ekanligi aniqlandi. Aniqlangan o‘zgarishlar ichak mikrobiomining neyroyallig‘lanish mexanizmlari va Parkinson kasalligi progressiyasidagi muhim rolini tasdiqlaydi hamda diagnostika va davolash yondashuvlarini ishlab chiqishda uni hisobga olish zarurligini asoslaydi.
Библиографические ссылки
Su D, Blacker D, Dorsey ER, et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:bmj-2024-080952. doi:10.1136/bmj-2024-080952.
Akhmedullin R, Supiyev A, et al. Burden of Parkinson’s disease in Central Asia from 1990 to 2021: findings from the Global Burden of Disease Study. BMC Neurology. 2024. doi:10.1186/s12883-024-03949-w.
Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015 Aug 29;386(9996):896–912. doi:10.1016/S0140-6736(14)61393-3.
Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235–245. doi:10.1016/S1474-4422(06)70373-8.
Roos DS, et al. Prevalence of Prodromal Symptoms of Parkinson’s Disease. J Parkinsons Dis. 2022; (review). (см. обзор данных о продромальных НМС и их значении). PMC доступно: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108586/
Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Medical records documentation of constipation preceding Parkinson disease: a case–control study. Neurology. 2009 Jun 9;73(9):1101–1105. doi:10.1212/WNL.0b013e3181b39d1b.
Mahmood Z, et al. REM Sleep Behavior Disorder in Parkinson’s Disease — review. J Clin Sleep Med. 2020; (review). PMC
доступно: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554050/
Berg D, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1600–1611. doi:10.1002/mds.26431.
Heinzel S, et al. Update of the MDS research criteria for prodromal Parkinson’s disease — review and integration of new evidence. Mov Disord. 2019;34(10):1451–1457. doi:10.1002/mds.27764.
Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Medical records documentation of constipation preceding Parkinson disease: a case–control study. Neurology. 2009;73(21):1752–1758. doi:10.1212/WNL.0b013e3181c34af5.
Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57(3):456–462. doi:10.1212/WNL.57.3.456.
Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46(3):559–564. doi:10.1016/j.nbd.2011.10.014.
Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic neuropathology in Parkinson’s disease. Neurogastroenterol Motil. 2010;22(7):741–e219. doi:10.1111/j.1365-2982.2010.01511.x.
Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe. 2015;17(5):565–576. doi:10.1016/j.chom.2015.04.011.
Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nat Rev Neurol. 2015;11(11):625–636. doi:10.1038/nrneurol.2015.197.
Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625–639. doi:10.1016/S1474-4422(15)00007-1.
Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3:31. doi:10.1186/s40168- 015-0094-5.
Sommer F, Bäckhed F. The gut microbiota—masters of host development and physiology. Nat Rev Microbiol. 2013;11(4):227–238. doi:10.1038/nrmicro2974.
Qin J., Li R., Raes J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464(7285): 59–65.
Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012; 489(7415): 220–230.
Arumugam M., Raes J., Pelletier E. et al. Enterotypes of the human gut microbiome. Nature. 2011; 473(7346): 174–180.
Falony G., Joossens M., Vieira-Silva S. et al. Population-level analysis of gut microbiome variation. Science. 2016; 352(6285): 560–564.
Sampson T. R., et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell. 2016;167(6):1469–1480.e12.
Bedarf J. R., et al. Functional implications of microbial changes in the gut of patients with Parkinson’s disease. npj Parkinson’s Disease. 2017;3:11.
Осипов Г. А., Тарасова И. А., Козлова Е. А. Современные подходы к исследованию микробиоты человека методом хромато-масс-спектрометрии. Микробиология, 2021; 90(3): 287–295.
Qian Y. et al. Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease. Brain, Behavior, and Immunity, 2020; 91: 324–334.
Zuo T., Ng S.C. The gut mycobiome in health and disease. Expert Review of Gastroenterology & Hepatology, 2018; 12(8): 757–769.
Hasegawa S. et al. Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson’s Disease. PLOS ONE. 2015;10(11):e0142164.
(Frontiers) Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease. Frontiers in Neuroscience. 2015.
Lipopolysaccharide-binding protein and future Parkinson’s disease risk: a European prospective cohort. Journal of Neuroinflammation. 2023.
How leaky is the gut in Parkinson’s disease? eBioMedicine (The Lancet). 2025.
Mawatari S. et al. Decreases of ethanolamine plasmalogen and phosphatidylcholine in erythrocyte are a common phenomenon in Alzheimer’s, Parkinson’s, and coronary artery diseases. Brain Research Bulletin. 2022. doi:10.1016/j.brainresbull.2022.08.009
Alterations of the gut virome in patients with Parkinson’s disease. Research Square (preprint). 2025.
Forsyth C.B. et al. Increased intestinal permeability correlates with sigmoid mucosa α-synuclein staining and endotoxin exposure in Parkinson’s disease. PLoS One. 2011.
Hasegawa S. et al. Intestinal dysbiosis and lowered serum LPS-binding protein in Parkinson’s disease. PLoS One. 2015.
Cani P.D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007.
Cryan J.F., Dinan T.G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012.
Sampson T.R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016.
Scheperjans F. et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015.
Keshavarzian A. et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015.
Bedarf J.R. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients. Genome Medicine. 2017.
Lloyd-Price J. et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature. 2017.
Lozupone C.A. et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012.
